Vice President of Clinical Development
Denis O’Shaughnessy is VP of Clinical Development at Aura. Most recently, he was responsible for the clinical development program for Oraya’s stereotactic radiotherapy device, resulting in its commercialization for wet age-related macular degeneration (AMD) in Europe. Before that, Denis was a founding member of Eyetech Pharmaceuticals, where he was responsible for overseeing the successful clinical development program for Macugen®. Prior to his role at Eyetech, he was a Clinical Leader for Hoffmann La Roche’s oncology group in Strasbourg, France. During his ten-year tenure at Hoffmann La Roche, Denis was responsible for initiating the first-ever clinical research program for a pharmaceutical agent in retinal disease: alpha interferon for the treatment of wet AMD. Earlier in his career, Denis worked in positions of increasing responsibility as the Head of Clinical Development at Celltech Limited in the United Kingdom, Xoma, Sandoz and the American Cyanmid’s European Regional Office in London. Denis earned his BS in Physiology and Biochemistry at London University and his Ph.D. in Physiology from the Royal Postgraduate Medical School of London.